Use of granulocyte-macrophage colony-stimulating factor to reverse anergy in otherwise immunologically healthy children (Q56786254)

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Colony-stimulating factors: beyond the effects on hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Regulation of HLA-DR and co-stimulatory molecule expression on natural killer T cells by granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood p

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

The effects of rhGM-CSF on macrophage function

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Clinical applications of hematopoietic growth factors in pediatric oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, an

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Cytokines as clinical adjuvants: how far are we?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Macrophage defences against respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Noncytolytic control of viral infections by the innate and adaptive immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Immunophenotyping of normal lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Delayed cutaneous hypersensitivity in normals: choice of antigens and comparison to in vitro assays of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Monitoring cellular immune function in HIV infection by the delayed hypersensitivity skin test: Alternative to the CD4+ T-cell count?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Tetanus toxoid skin test in children: correlation with in vitro lymphocyte stimulation and monocyte chemotaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Immunopathogenesis of delayed-type hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

1 reference

7 January 2021

T cell anergy and costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Delayed-type hypersensitivity skin testing in human immunodeficiency virus-infected pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

The delayed hypersensitivity response and host resistance in surgical patients. 20 years later

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Hypersensitivity to tetanus toxoid

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

T lymphocyte anergy during acute infectious mononucleosis is restricted to the clonotypic receptor activation pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Effect of Measles Virus Infection on MHC Class II Expression and antigen Presentation in Human Monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Changes within T cell receptor V beta subsets in infants following measles vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Mechanism of suppression of cell-mediated immunity by measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Measles virus exploits dendritic cells to suppress CD4+ T-cell proliferation via expression of surface viral glycoproteins independently of T-cell trans-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Immunosuppression after measles vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

CD4 T cell responses to influenza infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Lymphocyte and mast cell counts are increased in the nasal mucosa in symptomatic natural colds.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Cellular immunity and memory to respiratory virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Human major group rhinoviruses downmodulate the accessory function of monocytes by inducing IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Rhinovirus and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Type 1 T regulatory cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Induction of T cell anergy by the treatment with IL-10-treated dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Human anergic CD4+ T cells can act as suppressor cells by affecting autologous dendritic cell conditioning and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Granulocyte-macrophage colony-stimulating factor modulates lipopolysaccharide (LPS)-binding and LPS-response of human macrophages: inverse regulation of tumour necrosis factor-alpha and interleukin-10

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960885-X

7 January 2021